{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:53:47Z","timestamp":1787007227171,"version":"build-2736575974"},"reference-count":134,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2021,10,3]]},"DOI":"10.1080\/14740338.2021.1924147","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T02:59:14Z","timestamp":1619665154000},"page":"1147-1161","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs"],"prefix":"10.1080","volume":"20","author":[{"given":"Zachary E.","family":"Holcomb","sequence":"first","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Combined Dermatology Residency Program, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA"},{"name":"Department of Dermatology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[{"name":"Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA"},{"name":"Department of Dermatology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12787"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.07.027"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90321-7"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.020"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00087.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1126\/science.1196284"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.255"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17093"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix285"},{"key":"cit0010","volume-title":"Dermatologic surgery, principles and practice","author":"Hurley H","year":"1989"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05390.x"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"cit0015","unstructured":"Humira (adalimumab) injection for subcutaneous use. Chicago (IL): AbbVie, Inc; [cited 2020 December 19]. Updated March 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125057s415lbl.pdf."},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0749"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S111019"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04545.x"},{"issue":"5","key":"cit0021","first-page":"s15","volume":"11","author":"Christina Goussi M","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10339.x"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14997"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0502-4"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15605"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1734560"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2018.7859"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.49"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04638.x"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01145-8"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14146"},{"issue":"4","key":"cit0035","first-page":"21","volume":"21","author":"Pena ZG","year":"2015","journal-title":"Dermatol Online J"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.014"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18983"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.09.071"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.050"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08332.x"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.022"},{"key":"cit0044","volume-title":"Remicade (infliximab) for injection, for intravenous use"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0366-9"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.6.8.797"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"issue":"12","key":"cit0049","first-page":"1137","volume":"7","author":"Menter A","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02313.x"},{"key":"cit0051","volume-title":"Kineret (anakinra) injection, for subcutaneous use"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.044"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14596"},{"key":"cit0055","volume-title":"Stelara (ustekinumab) injection, for subcutaneous or intravenous use"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14338"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"cit0058","volume-title":"Cosentyx (secukinumab) injection, for subcutaneous use"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(14)70016-X"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17822"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17178"},{"key":"cit0064","unstructured":"ClinicalTrials.gov. Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimes of Secukinumab in subjects with Hidradenitis Suppurativa. Identifier: NCT04179175."},{"key":"cit0065","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of two Secukinumab dose regimens in subjects with moderate to severe Hidradenitis Suppurativa (HS) (SUNRISE). Identifier: NCT03713632."},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923"},{"key":"cit0067","unstructured":"Tremfya (guselkumab) injection for subcutaneous use. Janssen Biotech, Inc; [cited 2020 December 31]. Updated July 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761061s007lbl.pdf."},{"key":"cit0068","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of guselkumab for the treatment of participants with moderate to severe hidradenitis suppurativa (HS) (NOVA). Identifier NCT03628924."},{"key":"cit0069","unstructured":"ClinicalTrials.gov. Guselkumab for hidradenitis suppurativa, a mode of action study (HiGUS). Identifier NCT04061395."},{"key":"cit0070","unstructured":"ClinicalTrials.gov. Biomarkers in participants with hidradenitis suppurativa receiving guselkumab. Identifier NCT04084665."},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.017"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15368"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu007"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2010.00946.x"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2008.00669.x"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00172.x"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.002"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12642"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.973399"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12872"},{"issue":"10","key":"cit0082","first-page":"1240","volume":"11","author":"Andrulonis R","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17086"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12895"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx141"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex305"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key093"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16901"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S6029"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.171"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.05.040"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0363-5"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.04.014"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex510"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13767"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.11.043"},{"issue":"11","key":"cit0097","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5070\/D32411041999","volume":"24","author":"Bartos G","year":"2018","journal-title":"Dermatol Online J"},{"key":"cit0098","first-page":"646","volume":"17","author":"Di Lernia V","year":"2019","journal-title":"J Deutschen Dermatologischen Gesellschaft= J Ger Soc Dermatol: JDDG"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.579085"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12531"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12045"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182380a76"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.037"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17444"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13401"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14608"},{"issue":"9","key":"cit0107","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5070\/D3249041421","volume":"24","author":"Feaster B","year":"2018","journal-title":"Dermatol Online J"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12461"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12601"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2939"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0671-z"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2989"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.085"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.999"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009567"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.043"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.007"},{"key":"cit0118","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of Bimekizumab in study participants with moderate to severe Hidradenitis Suppurativa (BE HEARD I). Identifier: NCT04242446."},{"key":"cit0119","unstructured":"ClinicalTrials.gov. Treatment of moderate Hidradenitis Suppurativa. Identifier: NCT03910803."},{"key":"cit0120","unstructured":"ClinicalTrials.gov. Efficacy, safety, and pharmacokinetics study of CJM112 in Hidradenitis Suppurativa patients. Identifier: NCT02421172."},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70155-X"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.030"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.10.024"},{"key":"cit0124","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of Bermekimab in patients with Hidradenitis Suppurativa. Identifier NCT04019041."},{"key":"cit0125","unstructured":"ClinicalTrials.gov. A global study comparing Risankizumab to Placebo in adult participants with moderate to severe Hidradenitis Suppurativa (DETERMINED 1). Identifier: NCT03926169."},{"key":"cit0126","unstructured":"ClinicalTrials.gov. A study of oral Upadacitinib tablet compared to Placebo in adult participants with moderate to severe Hidradenitis Suppurativa to assess change in disease symptoms. Identifier: NCT04430855."},{"key":"cit0127","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and efficacy of PF-06650833, PF-06700841, and PF 06826647 in adults with Hidradenitis Suppurativa. Identifier: NCT04092452."},{"key":"cit0128","unstructured":"ClinicalTrials.gov. A Placebo-controlled study of the safety of INCB054707 in participants with Hidradenitis Suppurativa. Identifier: NCT03607487."},{"key":"cit0129","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of investigational treatments in patients with moderate to severe Hidradenitis Suppurativa. Identifier: NCT03827798."},{"key":"cit0130","unstructured":"ClinicalTrials.gov. Evaluation of safety and efficacy of Avacopan in subjects with moderate to severe Hidradenitis Suppurativa (AURORA). Identifier: NCT03852472."},{"key":"cit0131","unstructured":"ClinicalTrials.gov. Efficacy and safety study of IFX-1 in patients with moderate to severe Hidradenitis Suppurativa (HS) (SHINE). Identifier: NCT03487276."},{"key":"cit0132","unstructured":"ClinicalTrials.gov. A study of LY3041658 in adults with Hidradenitis Suppurativa. Identifier: NCT04493502."},{"key":"cit0133","unstructured":"ClinicalTrials.gov. Efficacy and safety of Efalizumab in the treatment of moderate-severe Hydradenitis Suppurativa. Identifier: NCT00134134."},{"key":"cit0134","unstructured":"ClinicalTrials.gov. Safety and Pharmacokinetics of repeat doses of CSL324 in subjects with Hidradenitis Suppurativa and Palmoplantar Pustulosis. Identifier: NCT03972280."}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2021.1924147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T15:51:26Z","timestamp":1671983486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2021.1924147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":134,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,3]]}},"alternative-id":["10.1080\/14740338.2021.1924147"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2021.1924147","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}